108 related articles for article (PubMed ID: 35519188)
1. Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19).
De Vita S; Chini MG; Lauro G; Bifulco G
RSC Adv; 2020 Nov; 10(67):40867-40875. PubMed ID: 35519188
[TBL] [Abstract][Full Text] [Related]
2. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
3. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
4. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
[TBL] [Abstract][Full Text] [Related]
5. Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease.
Oktay L; Erdemoğlu E; Tolu İ; Yumak Y; Özcan A; Acar E; Büyükkiliç Ş; Olkan A; Durdaği S
Turk J Biol; 2021; 45(4):459-468. PubMed ID: 34803447
[TBL] [Abstract][Full Text] [Related]
6. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target.
DurdaĞi S
Turk J Biol; 2020; 44(3):185-191. PubMed ID: 32595355
[TBL] [Abstract][Full Text] [Related]
7.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
8. Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.
Chowdhury KH; Chowdhury MR; Mahmud S; Tareq AM; Hanif NB; Banu N; Reza ASMA; Emran TB; Simal-Gandara J
Biology (Basel); 2020 Dec; 10(1):. PubMed ID: 33374717
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
Bepari AK; Reza HM
PeerJ; 2021; 9():e11261. PubMed ID: 33954055
[TBL] [Abstract][Full Text] [Related]
10. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
[TBL] [Abstract][Full Text] [Related]
11. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
[TBL] [Abstract][Full Text] [Related]
12. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach.
Mittal L; Kumari A; Srivastava M; Singh M; Asthana S
J Biomol Struct Dyn; 2021 Jul; 39(10):3662-3680. PubMed ID: 32396769
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
[TBL] [Abstract][Full Text] [Related]
16. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
Shamsi A; Mohammad T; Anwar S; AlAjmi MF; Hussain A; Rehman MT; Islam A; Hassan MI
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32441299
[TBL] [Abstract][Full Text] [Related]
17. Phenylbenzopyrone of Flavonoids as a Potential Scaffold to Prevent SARSCoV-2 Replication by Inhibiting its M
Potshangbam AM; Nongdam P; Kumar AK; Rathore RS
Curr Pharm Biotechnol; 2021; 22(15):2054-2070. PubMed ID: 33504301
[TBL] [Abstract][Full Text] [Related]
18. In Silico Prediction of Novel Inhibitors of SARS-CoV-2 Main Protease through Structure-Based Virtual Screening and Molecular Dynamic Simulation.
Halim SA; Waqas M; Khan A; Al-Harrasi A
Pharmaceuticals (Basel); 2021 Sep; 14(9):. PubMed ID: 34577596
[TBL] [Abstract][Full Text] [Related]
19. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
J A; Francis D; C S S; K G A; C S; Variyar EJ
J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
[TBL] [Abstract][Full Text] [Related]
20. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.
Kalhotra P; Chittepu VCSR; Osorio-Revilla G; Gallardo-Velazquez T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33578831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
